CN115916146A - 白发抑制用组合物及其用途 - Google Patents
白发抑制用组合物及其用途 Download PDFInfo
- Publication number
- CN115916146A CN115916146A CN202080101323.3A CN202080101323A CN115916146A CN 115916146 A CN115916146 A CN 115916146A CN 202080101323 A CN202080101323 A CN 202080101323A CN 115916146 A CN115916146 A CN 115916146A
- Authority
- CN
- China
- Prior art keywords
- composition
- white hair
- hair
- suppressing
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 150
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 44
- 108060000903 Beta-catenin Proteins 0.000 claims abstract description 11
- 102000015735 Beta-catenin Human genes 0.000 claims abstract description 11
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 claims description 18
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims description 17
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims description 17
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims description 17
- QLDAACVSUMUMOR-UHFFFAOYSA-M 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 QLDAACVSUMUMOR-UHFFFAOYSA-M 0.000 claims description 17
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims description 17
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims description 17
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims description 17
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 17
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims description 17
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims description 17
- 229940058690 lanosterol Drugs 0.000 claims description 17
- STKUCSFEBXPTAY-GSUVRYNNSA-N methyl (4s,5z,6s)-5-ethylidene-4-[2-oxo-2-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate Chemical compound O([C@@H]\1OC=C([C@H](C/1=C/C)CC(=O)OC[C@@H]1[C@H]([C@H](O)[C@@H](O)[C@H](OCCC=2C=CC(O)=CC=2)O1)O)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O STKUCSFEBXPTAY-GSUVRYNNSA-N 0.000 claims description 16
- KWBPKUMWVXUSCA-AXQDKOMKSA-N 3-[(3s,5s,8r,9s,10r,13r,14s,17r)-5,14-dihydroxy-3-[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@@H](C[C@@]5(O)CC[C@H]4[C@@]3(O)CC2)O[C@H]2C[C@@H]([C@@H]([C@@H](C)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)OC)=CC(=O)OC1 KWBPKUMWVXUSCA-AXQDKOMKSA-N 0.000 claims description 15
- LMZSCLAHNSQLBW-UHFFFAOYSA-N periplocin Natural products COC1CC(OC2CCC3(C)C(CCC4C3CCC5(C)C(CCC45C)C6=CC(=O)OC6)C2)OC(C)C1OC7OC(CO)C(O)C(O)C7O LMZSCLAHNSQLBW-UHFFFAOYSA-N 0.000 claims description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 15
- 229930182490 saponin Natural products 0.000 claims description 15
- 150000007949 saponins Chemical class 0.000 claims description 15
- VQUPQWGKORWZII-WDPYGAQVSA-N (2r,3r)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C=C1 VQUPQWGKORWZII-WDPYGAQVSA-N 0.000 claims description 14
- VQUPQWGKORWZII-KTLFEHCLSA-N Dihydrokaempferol-3-O-alpha-L-rhamnopyranoside Natural products O([C@@H]1[C@H](c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VQUPQWGKORWZII-KTLFEHCLSA-N 0.000 claims description 14
- VQUPQWGKORWZII-UHFFFAOYSA-N Neoisoengelitin Natural products OC1C(O)C(O)C(C)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C=C1 VQUPQWGKORWZII-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 229940011399 escin Drugs 0.000 claims description 12
- 229930186222 escin Natural products 0.000 claims description 12
- XZVXEPPPQBLGMQ-HISQCTEXSA-N methyl (1ar,1bs,2s,5ar,6r,6as)-5a,6-dihydroxy-1a-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1b,2,6,6a-tetrahydrooxireno[1,2]cyclopenta[4,5-c]pyran-5-carboxylate Chemical compound O([C@@H]1OC=C([C@]2([C@H](O)[C@@H]3O[C@]3(C)[C@H]21)O)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XZVXEPPPQBLGMQ-HISQCTEXSA-N 0.000 claims description 11
- XZVXEPPPQBLGMQ-UHFFFAOYSA-N sesamoside Natural products C12C3(C)OC3C(O)C2(O)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O XZVXEPPPQBLGMQ-UHFFFAOYSA-N 0.000 claims description 11
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 claims description 9
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 claims description 9
- 101710163504 Phaseolin Proteins 0.000 claims description 9
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 claims description 9
- 230000001629 suppression Effects 0.000 claims description 9
- 241001645380 Bassia scoparia Species 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
- 229930188006 polyphyllin Natural products 0.000 claims description 8
- GCMGJWLOGKSUGX-RBKCHLQLSA-N 26-Deoxyactein Chemical compound O([C@H]1CC[C@@]23[C@H](C1(C)C)CC[C@H]1[C@]4(C)C[C@@H]5O[C@]6([C@@H]7O[C@]7(C)CO6)C[C@H]([C@@H]5[C@@]4(C)[C@H](OC(C)=O)C[C@]12C3)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O GCMGJWLOGKSUGX-RBKCHLQLSA-N 0.000 claims description 7
- CVWMSOSSLBOGFK-UHFFFAOYSA-N 27-deoxyactein Natural products CC1CC2(OCC3(C)OC23)OC4C(O)C5(C)C6CCC7C(C)(C)C(CCC78CC68CC(OC(=O)C)C5(C)C14)OC9OCC(O)C(O)C9O CVWMSOSSLBOGFK-UHFFFAOYSA-N 0.000 claims description 7
- HWYBGIDROCYPOE-WEAQAMGWSA-N Momordin ic Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O HWYBGIDROCYPOE-WEAQAMGWSA-N 0.000 claims description 7
- 241000244269 Peucedanum Species 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 7
- HWYBGIDROCYPOE-UHFFFAOYSA-N momordin Ic Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC(C1O)OC(C(O)=O)C(O)C1OC1OCC(O)C(O)C1O HWYBGIDROCYPOE-UHFFFAOYSA-N 0.000 claims description 7
- 210000004761 scalp Anatomy 0.000 claims description 7
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims description 6
- 229930182432 Polygalasaponin Natural products 0.000 claims description 6
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims description 6
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims description 6
- PNTWXEIQXBRCPS-UHFFFAOYSA-N Calipteryxin Natural products C1=CC(=O)OC2=C3C(OC(=O)C(C)=CC)C(OC(=O)C(C)=CC)C(C)(C)OC3=CC=C21 PNTWXEIQXBRCPS-UHFFFAOYSA-N 0.000 claims description 5
- PNTWXEIQXBRCPS-FNCQTZNRSA-N [8,8-dimethyl-9-[(e)-2-methylbut-2-enoyl]oxy-2-oxo-9,10-dihydropyrano[2,3-f]chromen-10-yl] (e)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C3C(OC(=O)C(/C)=C/C)C(OC(=O)C(\C)=C\C)C(C)(C)OC3=CC=C21 PNTWXEIQXBRCPS-FNCQTZNRSA-N 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 4
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 3
- CFUPNMDNSQIWBB-FYDLUACKSA-N Tussilagone Natural products CCC(=C/C(=O)O[C@@H]1C[C@@H](C(C)C)[C@H]2[C@@H](CC(=O)[C@@H]2[C@@H](C)OC(=O)C)C1=C)C CFUPNMDNSQIWBB-FYDLUACKSA-N 0.000 claims description 3
- CFUPNMDNSQIWBB-UUVDBSHOSA-N [(1S,3aR,5R,7S,7aS)-1-[(1R)-1-acetyloxyethyl]-4-methylidene-2-oxo-7-propan-2-yl-3,3a,5,6,7,7a-hexahydro-1H-inden-5-yl] (E)-3-methylpent-2-enoate Chemical compound CC\C(C)=C\C(=O)O[C@@H]1C[C@@H](C(C)C)[C@H]2[C@@H](CC(=O)[C@@H]2[C@@H](C)OC(C)=O)C1=C CFUPNMDNSQIWBB-UUVDBSHOSA-N 0.000 claims description 3
- BDCUGHMNUOTFKX-YJGMJMKZSA-N [(2s,3r,4s,5s)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl] (4ar,5r,6ar,6as,6br,8ar,9r,10r,11s,12ar,14bs)-5,11-dihy Polymers O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(CO)C)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BDCUGHMNUOTFKX-YJGMJMKZSA-N 0.000 claims description 3
- BDCUGHMNUOTFKX-DDRWPPTGSA-N polygalacin D Polymers O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@]1(CO)C)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BDCUGHMNUOTFKX-DDRWPPTGSA-N 0.000 claims description 3
- DJPJACADAIGMKF-CTELNEMLSA-N polygalacin-D Natural products O=C(O[C@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@]4(O)[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2 DJPJACADAIGMKF-CTELNEMLSA-N 0.000 claims description 3
- WEUAMJXXXHKXGE-XPKPLUMOSA-N polygalin D Natural products COc1cc(O)c2C(=O)C(=C(Oc2c1)c3ccc(OC)c(O)c3)O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]5OC[C@](O)(CO)[C@H]5O WEUAMJXXXHKXGE-XPKPLUMOSA-N 0.000 claims description 3
- 229930185045 praeruptorin Natural products 0.000 claims description 3
- 235000006751 Platycodon Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229930189914 platycodon Natural products 0.000 claims description 2
- ZRJLCVQCZVXUFB-UHFFFAOYSA-N (s)-valerianine Chemical compound COCC1=CN=CC2=C1CCC2C ZRJLCVQCZVXUFB-UHFFFAOYSA-N 0.000 claims 1
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 claims 1
- 241000244987 Daiswa polyphylla Species 0.000 claims 1
- 241000110847 Kochia Species 0.000 claims 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims 1
- 240000000377 Tussilago farfara Species 0.000 claims 1
- 235000004869 Tussilago farfara Nutrition 0.000 claims 1
- KRFBMPVGAYGGJE-UHFFFAOYSA-N nevadensin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(O)C(OC)=C2O1 KRFBMPVGAYGGJE-UHFFFAOYSA-N 0.000 claims 1
- FRZBKSSGEGEIAN-UHFFFAOYSA-N nevadensin Natural products COc1cccc(c1)-c1cc(=O)c2c(O)c(OC)c(O)c(OC)c2o1 FRZBKSSGEGEIAN-UHFFFAOYSA-N 0.000 claims 1
- 229930189618 valerianin Natural products 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 230000008099 melanin synthesis Effects 0.000 abstract description 13
- 230000003213 activating effect Effects 0.000 abstract description 4
- 230000019491 signal transduction Effects 0.000 abstract description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 15
- 102000013814 Wnt Human genes 0.000 description 14
- 108050003627 Wnt Proteins 0.000 description 14
- 210000002752 melanocyte Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- -1 3-butyl Chemical group 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000001256 tonic effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 7
- PXQNZQURQNZGKZ-UHFFFAOYSA-N 3-O-beta-Laminaribiosyl-platycodin-D(2) Natural products OC1C(O)C(OC2C(C(OC3C(C(O)(CO)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(CO)CO)O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O PXQNZQURQNZGKZ-UHFFFAOYSA-N 0.000 description 6
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 6
- YLHQFGOOMKJFLP-LTFXOGOQSA-N Rotundic acid Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C YLHQFGOOMKJFLP-LTFXOGOQSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- YQBNJPACAUPNLV-UHFFFAOYSA-N peucedanin Chemical compound O1C(=O)C=CC2=C1C=C1OC(C(C)C)=C(OC)C1=C2 YQBNJPACAUPNLV-UHFFFAOYSA-N 0.000 description 6
- PXQNZQURQNZGKZ-MXNHKPIDSA-N platycodin D2 Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PXQNZQURQNZGKZ-MXNHKPIDSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 4
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 108010051081 dopachrome isomerase Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- YLHQFGOOMKJFLP-UHFFFAOYSA-N ilexolic acid A Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C YLHQFGOOMKJFLP-UHFFFAOYSA-N 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- GJWSUKYXUMVMGX-UHFFFAOYSA-N citronellic acid Chemical compound OC(=O)CC(C)CCC=C(C)C GJWSUKYXUMVMGX-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000118 hair dye Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000002741 leukoplakia Diseases 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000003797 telogen phase Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000721153 Chloranthus japonicus Species 0.000 description 1
- 241000521299 Deinocerites cancer Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 241000544912 Melanoides Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- LWNOIQJAJMHMSM-UHFFFAOYSA-N Pariphyllin Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1OC2C(C(O)C(CO)O2)O)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O LWNOIQJAJMHMSM-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003681 hair reduction Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229930189407 platycodin Natural products 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000004059 quinone derivatives Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
- A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
本发明涉及具有优异的抑制白发产生的效果的白发抑制用组合物及其用途。本发明的白发抑制用组合物通过激活Wnt/β‑连环蛋白信号传导途径促进头发中黑色素的合成，从而具有显著优异的抑制、预防、改善、缓解、延迟或治疗白发(白毛症)的效果。
Description
技术领域
本发明涉及具有优异的抑制白发产生的效果的白发抑制用组合物及其用途。
背景技术
白发随着头皮老化的进行而产生。白发包括白毛症(灰发症，Canities)和头发灰化(头发变白，Hair Graying)。白发(白毛)根据其程度，使有白发的人看起来比实际年龄要老。头发的颜色变化可被认为是老化的信号，与年龄不符的白发的产生会对个人带来压力，对自尊心产生负面影响。因此，正在进行用于美容上改善白发的各种研究和开发。
即使为了改善白发而进行染发，随着头发的生长，白发也会持续生长，因此染发方法具有效果暂时的缺点。因此，上述染发方法还具有需要定期染发的缺点。另外，常规的氧化型染发剂有可能损伤头皮和皮肤。另外，黑豆或赤何首乌提取物等被用来改善白发，但缺点是效果不足以体感到。
白发产生的主要原因是黑素细胞干细胞(Melanocyte stem cell；MSC)的丢失或黑素细胞(Melanocyte)的生理活性降低。由此，由头发、眉毛或睫毛等的母毛中存在的黑素细胞生成的黑色素(Melanin)的量减少，因此进行头发的白化或灰白化。由黑素细胞生成的黑色素被传递到角质形成细胞(Keratinocyte)中，形成色素沉着的头发(Head hair)或体毛(Body hair)。此时，如果黑色素无法移动到角质形成细胞，则头发的色素会缺乏，从而产生白发。
呈现棕色和黑色的真黑色素(Umelanins)和呈现黄色和红色的类黑色素(Phenomelanins)的量和相对比例对头发和体毛的颜色产生很大的影响。并且已知，酪氨酸酶(Tyrosinase)、DHICA氧化酶(DHICA oxidase,TRP-1)和多巴色素互变异构酶(DOPAchrome tautomerase；TRP-2)的三种酶参与黑色素的生成，并且上述酶的活性会对黑色素的合成产生影响。在上述过程中，酪氨酸酶催化酪氨酸(Tyrosine)氧化成DOPA，并且DOPA氧化成多巴醌(dopaquinone)。称为L-多巴醌(L-Dopaquinone)或o-多巴醌的这种物质是黑色素的前体(precursor)。上述多巴醌在半胱氨酸(cysteine)存在的情况下自然环化(cyclization)成为多巴色素(dopachrome)，其通过多巴色素互变异构酶(TRP-2)互变异构形成DHICA。TRP-1氧化上述DHICA，形成醌衍生物。
在上述酶中，酪氨酸酶和TRP-1在毛囊生长周期中的生长期(anagen)期间在毛球(hair bulb)和毛乳头(Dermal papilla)周围的黑素细胞中表达，而在退行期(catagen)和休止期(telogen)期间不表达。
如前所述，白发受黑素细胞和黑素细胞干细胞的影响。另外，如果黑色素细胞减少，则由此黑色素的生成逐渐减少，黑色素的传递减少。这种黑色素的减少在皮肤上还表现为色素性疾病。作为色素性疾病的代表性实例，有白斑症(vitiligo)，而作为白斑症的原因之一，有黑素细胞的减少或破坏。而且，作为治疗这种白斑症的方法，Wnt/β-连环蛋白途径的激活被大量研究(Journal of Investigative Dermatology(2015)135,2921-2923)。另外，据报道，如果激活黑素细胞干细胞的Wnt信号传导机制，则头发和表皮黑素细胞(epidermal melanocyte)的色素生成会增加(Cell,Vol 145,Issue 6,10,(2011),941～955)(Medical Research Review(2016),Vol37,issue4,907～945)。
发明内容
技术课题
本发明要解决的课题是提供一种能够有效地抑制白发产生的白发抑制用组合物。
另外，本发明要解决的课题是提供一种上述组合物用于抑制白发产生的用途。
技术方案
本发明的发明人为了发掘能够有效地抑制包括上述白毛症在内的白发的物质，经过不懈的研究努力，其结果，发现了本发明的七叶皂苷(Escin)、27-脱氧升麻亭(27-Deoxyactein)、岩豆素(Lysionotin)、氯化两面针碱(Nitidine chloride)、羊毛甾醇(Lanosterol)、黄杞苷(Engeletin)、特女贞苷(Specnuezhenide)、白花前胡乙素(Praeruptorin B)、罗通酸(Rotunic acid)、胡麻属苷(Sesamoside)、远志皂苷D(Polygalacin D)、地肤子皂苷Ic(Momordin Ic)、氯化缬草素(Valechlorine)、款冬酮(Tussilagone)、杠柳毒苷(Periplocin)、重楼皂苷VII(Polyphyllin VII)或桔梗皂苷D2(Platycodin D2)激活Wnt/β-连环蛋白途径。另外，发现了上述物质具有增加B-16小鼠黑色素瘤细胞中黑色素合成的效果。本发明的发明人确认了当将具有优异的Wnt/β-连环蛋白途径激活效果的上述物质中的任一种以上施用(或涂布)于皮肤时，抑制或改善白发的效果显著优异，从而完成了本发明。
本发明提供一种白发抑制用组合物，其包含选自由七叶皂苷(Escin)、27-脱氧升麻亭(27-Deoxyactein)、岩豆素(Lysionotin)、氯化两面针碱(Nitidine chloride)、羊毛甾醇(Lanosterol)、黄杞苷(Engeletin)、特女贞苷(Specnuezhenide)、白花前胡乙素(Praeruptorin B)、罗通酸(Rotunic acid)、胡麻属苷(Sesamoside)、远志皂苷D(Polygalacin D)、地肤子皂苷Ic(Momordin Ic)、氯化缬草素(Valechlorine)、款冬酮(Tussilagone)、杠柳毒苷(Periplocin)、重楼皂苷VII(Polyphyllin VII)和桔梗皂苷D2(Platycodin D2)组成的组中的一种以上。上述白发抑制用组合物可以包含上述一种以上的物质作为有效成分。
在本发明中，白发的“抑制”可意味着抑制白发的产生量或产生频率，或者抑制由黑发向白发变化或老化的过程。在一个实施例中，白发的“抑制”可意味着通过激活Wnt/β-连环蛋白途径促进头发中黑色素的合成。在一个实施例中，本发明的白发抑制用组合物可以用于白发(白毛症)的抑制、预防、改善、缓解、延迟或治疗等的用途，并且还可以不受限制地用于任何用途，只要是用于改善白发的美容目的即可。上述“预防”可意味着通过施用本发明的组合物延迟白发的产生、生长或增殖进程的所有行为。上述“治疗”可意味着通过施用本发明的组合物抑制白发的生长和增殖来使白发或白毛症好转或有利地改变的所有行为。
在一个实施例中，本发明的白发抑制用组合物可以包含相对于组合物总重量的0.0001至50重量％、优选地0.001至10重量％的上述选自由七叶皂苷(Escin)、27-脱氧升麻亭(27-Deoxyactein)、岩豆素(Lysionotin)、氯化两面针碱(Nitidine chloride)、羊毛甾醇(Lanosterol)、黄杞苷(Engeletin)、特女贞苷(Specnuezhenide)、白花前胡乙素(Praeruptorin B)、罗通酸(Rotunic acid)、胡麻属苷(Sesamoside)、远志皂苷D(Polygalacin D)、地肤子皂苷Ic(Momordin Ic)、氯化缬草素(Valechlorine)、款冬酮(Tussilagone)、杠柳毒苷(Periplocin)、重楼皂苷VII(Polyphyllin VII)和桔梗皂苷D2(Platycodin D2)组成的组中的一种以上。当上述物质的含量小于0.0001重量％时，抑制白发的效果微弱，当超过50重量％时，剂型的稳定性降低，因此不优选。
在一个实施例中，本发明的白发抑制用组合物可以用作医药组合物、医药外品组合物或化妆料组合物。另外，本发明的白发抑制用组合物通常还可以剂型化成可施用于皮肤的任意形式。优选地，本发明的白发抑制用组合物可以剂型化成皮肤外用剂的形式。例如，上述皮肤外用剂剂型可以制备成可施用于皮肤的剂型，例如液状、霜状、膏状或固体状等。另外，本发明的白发抑制用组合物可以作为头发或头皮用组合物或产品提供，例如，可以通过添加常规添加剂制备成用于抑制白发的洗发水、滋补剂(tonic)、头发调理剂(hairconditioner)、发露(hair lotion)、凝胶、发膜、霜、精华液、粉、喷雾、油、皂、液体清洁剂、液体染发剂类型或气溶胶类型等的组合物，但不限于此。在下述本发明的制备例1或2中，将白发抑制用组合物制备成头发滋补剂或发露的剂型。
在一个实施例中，当本发明的白发抑制用组合物是液状时，作为载体成分，可以包含溶剂、溶剂化剂或乳浊化剂等。上述载体成分可以包括选自由例如水、醇、碳酸乙酯、乙酸乙酯、苯甲醇、苯甲酸苄酯、丙二醇、1,3-丁基乙二醇油、甘油脂肪族酯、聚乙二醇或脱水山梨糖醇的脂肪酸酯等组成的组中的一种以上。上述醇可以使用通常使用的醇，优选地可以使用线型或分支型的C2-C4一元醇，更优选地可以使用乙醇或异丙醇，但不限于此。
在一个实施例中，当本发明的白发抑制用组合物的剂型是膏、霜或凝胶时，作为载体成分，可以使用动物性油、植物性油、蜡、石蜡、淀粉、黄芪胶、纤维素衍生物、聚乙二醇、硅酮、膨润土、二氧化硅、滑石或氧化锌等。另外，作为上述载体成分，可以使用醇。上述醇优选为异丙醇，但不限于此。
在一个实施例中，当本发明的白发抑制用组合物的剂型是粉或喷雾时，作为载体成分，可以包含乳糖、滑石、二氧化硅、氢氧化铝、硅酸钙或聚酰胺粉。当上述剂型是喷雾时，可以进一步包含推进剂，例如氯氟烃、丙烷/丁烷或二甲醚等。
在一个实施例中，本发明的白发抑制用组合物可以包含通常可用于皮肤外用剂的成分，例如，可以额外地包含选自由水、表面活性剂、保湿剂、低级醇、螯合剂、杀菌剂、抗氧化剂、防腐剂、色素和香料组成的组中的一种以上的添加剂。
在一个实施例中，本发明的白发抑制用组合物可以以直接涂布或喷洒于皮肤等的经皮给药方法使用。上述术语“给药”是指本发明的白发抑制用组合物通过任何适当的方法引入身体内。本发明的白发抑制用组合物的给药途径可以通过任何常规途径给药，只要能够到达靶组织即可。优选地，本发明的白发抑制用组合物可以经皮给药，更优选地可以局部涂布。本发明的白发抑制用组合物的施用次数可以根据处方、需要或目的而决定。
在一个实施例中，本发明的白发抑制用组合物的使用量可以根据年龄或病变的程度等的个体差异或剂型而适当地调节。另外，对于本发明的白发抑制用组合物，优选通常1天1次至数次将适量涂布于头皮，使用1周至数月。在本发明的实验例3中，将白发抑制用组合物(头发滋补剂)每周7次，使用6个月。从上述实验例3的结果来看，确认了与比较例的安慰剂(placebo)对照群相比，在使用上述头发滋补剂时表现出优异的抑制白发的效果。特别是在包含乙醇的剂型中，确认了更高的防止脱发及头发生长的效果。
在一个实施例中，本发明提供一种白发抑制用试剂盒，其包含上述白发抑制用组合物。在另一个方面中，上述试剂盒是指包含预防或治疗白发所需的组合物和附属品的套装。在另一个方面中，上述试剂盒中包含的附属品是为了预防或治疗白发而在本发明所属的技术领域中通常使用的工具或装置等。在另一个方面中，上述试剂盒可以进一步包含服药指示书，该服药指示书公开了选自由上述成分的给药量、给药途径、给药次数和适应症(白毛症)等组成的组中的任一种以上。
在一个实施例中，本发明提供一种抑制白发的方法，包括将白发抑制用组合物施用于对象体。在另一个方面中，上述对象体可以是需要抑制白发的人类。优选地，在上述方法中，上述白发抑制用组合物可以以有效量施用于对象体。上述“有效量”意味着足以抑制、延迟、改善或缓解白发，或者在白发的治疗或管理中提供治疗上或美容上的益处的有效成分的量。上述“有效量”还意味着无论是体外(in vitro)还是体内(in vivo)都足以抑制或减少白发产生的量。上述抑制白发的方法可以通过激活Wnt/β-连环蛋白信号传导途径促进头发中黑色素的合成，从而表现出抑制或改善白发的效果。
在一个实施例中，本发明提供一种用于抑制白发的用途，其特征在于，利用上述白发抑制用组合物。在一个实施例中，上述用途可以包括用于抑制或改善白发的所有用途，例如可以包括医药用途、化妆学用途或美容学用途等。在另一个方面中，上述用于抑制白发的用途可以通过激活Wnt/β-连环蛋白信号传导途径促进头发中黑色素的合成，从而表现出抑制或改善白发的效果。
在一个实施例中，本发明提供一种制备白发抑制用组合物的方法，该组合物包含选自由七叶皂苷(Escin)、27-脱氧升麻亭(27-Deoxyactein)、岩豆素(Lysionotin)、氯化两面针碱(Nitidine chloride)、羊毛甾醇(Lanosterol)、黄杞苷(Engeletin)、特女贞苷(Specnuezhenide)、白花前胡乙素(Praeruptorin B)、罗通酸(Rotunic acid)、胡麻属苷(Sesamoside)、远志皂苷D(Polygalacin D)、地肤子皂苷Ic(Momordin Ic)、氯化缬草素(Valechlorine)、款冬酮(Tussilagone)、杠柳毒苷(Periplocin)、重楼皂苷VII(Polyphyllin VII)和桔梗皂苷D2(Platycodin D2)组成的组中的一种以上。在上述制备方法中，白发抑制用组合物可以根据通常使用的化妆品、医药外品或医药品等的制备方法制备。
在一个实施例中，本发明的白发抑制用组合物可以包含选自由七叶皂苷(Escin)、27-脱氧升麻亭(27-Deoxyactein)、岩豆素(Lysionotin)、氯化两面针碱(Nitidinechloride)、羊毛甾醇(Lanosterol)、黄杞苷(Engeletin)、特女贞苷(Specnuezhenide)、白花前胡乙素(Praeruptorin B)、罗通酸(Rotunic acid)、胡麻属苷(Sesamoside)、远志皂苷D(Polygalacin D)、地肤子皂苷Ic(Momordin Ic)、氯化缬草素(Valechlorine)、款冬酮(Tussilagone)、杠柳毒苷(Periplocin)、重楼皂苷VII(Polyphyllin VII)和桔梗皂苷D2(Platycodin D2)组成的组中的两种以上。
在一个实施例中，在本发明的白发抑制用组合物中，记载的所有成分的含量优选不超过化妆品/食品/医药品/医药外品相关的各种规范中规定的最大使用值。
发明效果
本发明的白发抑制用组合物能够有效地抑制白发的产生。本发明的白发抑制用组合物通过激活Wnt/β-连环蛋白信号传导途径促进头发中黑色素的合成，从而具有显著优异的抑制、预防、改善、缓解、延迟或治疗白发(白毛症)的效果。
附图说明
图1是确认在B-16黑色素瘤细胞中因七叶皂苷而导致黑色素合成增加的实验结果。
图2是显示根据七叶皂苷及其含量的黑色素合成量增加的图。
具体实施方式
以下，为了便于理解本发明，将例举实施例等进行详细说明。但是，根据本发明的实施例可以变形为各种其他形式，并且本发明的范围不应被解释为限于下述实施例。本发明的实施例是为了向本领域的普通技术人员更加完整地说明本发明而提供的。
实验例1：Wnt/β-连环蛋白信号传导增加效果
在本实验中，为了确认Wnt/β-连环蛋白途径的激活，使用了TCF/LEF响应荧光素酶报告基因HEK293A(TCF/LEF Responsive Luciferase Reporter HEK293A)稳定细胞株(Wnt报告基因HEK293A细胞；WRHEK293A)。本稳定细胞株使用MEM(Corning,USA)和胎牛血清(Fetal bovine serum)(Gibco BRL,盖瑟斯堡,MD,USA)进行继代培养来维持。为了转录活性试验法，在96-孔板(well plate)中每孔接种3万个细胞后，在37℃的培养箱中培养24小时。并且如表1所示，分别处理了本发明的七叶皂苷、27-脱氧升麻亭、岩豆素、氯化两面针碱、羊毛甾醇、黄杞苷、特女贞苷、白花前胡乙素、罗通酸、胡麻属苷、远志皂苷D、地肤子皂苷Ic、氯化缬草素、款冬酮、杠柳毒苷、重楼皂苷VII和桔梗皂苷D2。之后培养24小时，然后使用荧光素酶分析系统(Luciferase assay system,Promega)进行报告分析。根据制造商的实验方法进行，利用维克多多壁酶标仪(Victor multiwall plate reader)(PerkinElmer,USA)测量发光(Luminescence)。为了确认物质处理引起的细胞毒性，并行测量了GFP的荧光(Fluorescence)表达作为内部对照群(internal control)。将发光酶的反应引起的发光值除以GFP荧光值，然后将未处理对照群的值设为100％，求出与此相比的处理群的值并用百分比(％)表示(表1)。
[表1]
Wnt/β-连环蛋白信号传导增加效果
实验例2：黑色素生成效果确认
在本实验中，将显示出Wnt信号传导增加效果的实验例1的化合物添加到源自小鼠的黑色素瘤细胞(B-16小鼠黑色素瘤细胞，B-16mouse melanoma cell)的培养液中，并测试细胞水平上的黑色素生成效果(Lotan R.,Lotan D.Cancer Res.40:3345-3350,1980)。实验前，对B-16黑色素瘤细胞进行毒性评价，选定没有毒性的浓度进行黑色素生成评价。B-16黑色素瘤细胞在包含10％ FBS的DMEM(Gibco BRL,盖瑟斯堡,MD,USA)中进行继代培养。之后，接种于100mm细胞培养皿中以进行黑色素合成和提取，然后在汇合度(conflucency)为70％时处理化合物。上述化合物在培养液中以10μg/mL的浓度处理。使用黑色素细胞刺激激素(α-melanocyte stimulating hormone,α-MSH)作为对照群，将其添加到培养液中使其达到10nM，然后分别处理于B-16黑色素瘤细胞中，培养48小时。之后，对细胞进行胰蛋白酶(trypsin)处理，从培养容器中摘取，然后离心分离以提取黑色素。向摘取的细胞加入1mL氢氧化钠溶液(1N浓度)并煮沸10分钟以溶解黑色素。利用分光光度计，在400nM处测量吸光度(absorbance)以测量生成的黑色素的量。上述黑色素量利用根据黑色素的浓度的标准吸光度曲线(standard curve)以μg/mL为单位进行定量。将未处理对照群计算为100％，求出与此相比的处理群的值并用百分比(％)表示(表2)。
[表2]
黑色素合成
上述化合物中七叶皂苷的黑色素合成结果示于图1和图2。
实验例3：白发抑制用组合物1(头发滋补剂)的抑制白发产生的效果确认试验
制备了包含本发明的化合物中的七叶皂苷和27-脱氧升麻亭的白发抑制用组合物1(头发滋补剂)。使用上述组合物测试了人体头发的白发减少效果。以60名有白发的健康成人为对象，每组12人分成5组，将比较例1、实施例1、实施例1-2、实施例2或实施例2-2每周7次使用于头皮6个月。使用后，利用头皮检测仪毛发摄像图(Folliscopephototrichogram)，评价了与组合物涂布前相比白发产生程度。对于实验结果，将涂布前设为100％，以与此相比的值示于表3。
[表3]
制备例1：白发抑制用组合物1(头发滋补剂)
将本发明的七叶皂苷、27-脱氧升麻亭、岩豆素、氯化两面针碱、羊毛甾醇、黄杞苷、特女贞苷、白花前胡乙素、罗通酸、胡麻属苷、远志皂苷D、地肤子皂苷Ic、氯化缬草素、款冬酮、杠柳毒苷、重楼皂苷VII或桔梗皂苷D2根据下表4所示的处方用常规方法制备头发滋补剂。
[表4]
制备例2：白发抑制用组合物2(发露)
将本发明的七叶皂苷、27-脱氧升麻亭、岩豆素、氯化两面针碱、羊毛甾醇、黄杞苷、特女贞苷、白花前胡乙素、罗通酸、胡麻属苷、远志皂苷D、地肤子皂苷Ic、氯化缬草素、款冬酮、杠柳毒苷、重楼皂苷VII或桔梗皂苷D2根据下表5所示的处方用常规方法制备发露。
[表5]
Claims (8)
1.一种白发抑制用组合物，其包含选自由七叶皂苷(Escin)、27-脱氧升麻亭(27-Deoxyactein)、岩豆素(Lysionotin)、氯化两面针碱(Nitidine chloride)、羊毛甾醇(Lanosterol)、黄杞苷(Engeletin)、特女贞苷(Specnuezhenide)、白花前胡乙素(Praeruptorin B)、罗通酸(Rotunic acid)、胡麻属苷(Sesamoside)、远志皂苷D(Polygalacin D)、地肤子皂苷Ic(Momordin Ic)、氯化缬草素(Valechlorine)、款冬酮(Tussilagone)、杠柳毒苷(Periplocin)、重楼皂苷VII(Polyphyllin VII)和桔梗皂苷D2(Platycodin D2)组成的组中的一种以上。
2.如权利要求1所述的白发抑制用组合物，其中，包含相对于组合物的总重量的0.0001至50重量％的所述选自由七叶皂苷(Escin)、27-脱氧升麻亭(27-Deoxyactein)、岩豆素(Lysionotin)、氯化两面针碱(Nitidine chloride)、羊毛甾醇(Lanosterol)、黄杞苷(Engeletin)、特女贞苷(Specnuezhenide)、白花前胡乙素(Praeruptorin B)、罗通酸(Rotunic acid)、胡麻属苷(Sesamoside)、远志皂苷D(Polygalacin D)、地肤子皂苷Ic(Momordin Ic)、氯化缬草素(Valechlorine)、款冬酮(Tussilagone)、杠柳毒苷(Periplocin)、重楼皂苷VII(Polyphyllin VII)和桔梗皂苷D2(Platycodin D2)组成的组中的一种以上。
3.如权利要求1所述的白发抑制用组合物，其中，所述白发抑制用组合物激活Wnt/β-连环蛋白信号传导系统。
4.如权利要求1所述的白发抑制用组合物，其中，所述白发抑制用组合物是医药组合物、医药外品组合物或化妆料组合物。
5.一种白发抑制用头发或头皮用产品，其包含权利要求1所述的白发抑制用组合物。
6.一种白发抑制用试剂盒，其包含权利要求1所述的白发抑制用组合物。
7.一种抑制白发的方法，包括将权利要求1所述的白发抑制用组合物施用于对象体。
8.一种权利要求1所述的白发抑制用组合物用于抑制白发的用途。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2020/006903 WO2021241780A1 (ko) | 2020-05-28 | 2020-05-28 | 흰머리 억제용 조성물 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115916146A true CN115916146A (zh) | 2023-04-04 |
Family
ID=78744900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080101323.3A Pending CN115916146A (zh) | 2020-05-28 | 2020-05-28 | 白发抑制用组合物及其用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230201097A1 (zh) |
| JP (1) | JP2023535534A (zh) |
| KR (1) | KR20230012482A (zh) |
| CN (1) | CN115916146A (zh) |
| WO (1) | WO2021241780A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115227702A (zh) * | 2022-08-02 | 2022-10-25 | 北京工商大学 | 重楼皂苷ⅶ在制备抗色素沉着的产品中的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452167A1 (de) * | 2003-02-28 | 2004-09-01 | Cognis France S.A. | Kosmetische, pharmazeutische und/oder dermatologische Zubereitungen enthaltend einen Extrakt aus Eperua falcata |
| KR102023021B1 (ko) * | 2016-02-25 | 2019-09-19 | 주식회사 엘지생활건강 | 하이드록시 데카노익애씨드를 포함하는 모발 성장 촉진용 화장료 또는 약학 조성물 |
| KR102690426B1 (ko) * | 2016-10-18 | 2024-07-31 | 주식회사 엘지생활건강 | 투실라곤을 포함하는 화장료 조성물 |
| KR102639155B1 (ko) * | 2016-10-26 | 2024-02-22 | 주식회사 엘지생활건강 | 발레클로린을 포함하는 화장료 조성물 |
| KR102063697B1 (ko) * | 2018-07-09 | 2020-01-08 | 주식회사 엘지생활건강 | 에스신을 포함하는 탈모 방지 및 발모 촉진용 조성물 |
-
2020
- 2020-05-28 CN CN202080101323.3A patent/CN115916146A/zh active Pending
- 2020-05-28 KR KR1020227039183A patent/KR20230012482A/ko active Search and Examination
- 2020-05-28 WO PCT/KR2020/006903 patent/WO2021241780A1/ko active Application Filing
- 2020-05-28 US US18/000,034 patent/US20230201097A1/en active Pending
- 2020-05-28 JP JP2022572787A patent/JP2023535534A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023535534A (ja) | 2023-08-18 |
| KR20230012482A (ko) | 2023-01-26 |
| WO2021241780A1 (ko) | 2021-12-02 |
| US20230201097A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101089071B1 (ko) | 백모증 처리를 위한 엘라그산의 용도 | |
| KR100930257B1 (ko) | 백모증 처리를 위한, 3ｈ-1,2-디티올-3-티온, 아네톨 디티올에티온, 설포라판, 펜에틸 이소티오시아네이트, 6-(메틸설피닐)헥실 이소티오시아네이트 및 알릴 이소티오시아네이트의 용도 | |
| KR102193209B1 (ko) | 갈대 추출물을 유효성분으로 포함하는 피부 미백용 화장료 조성물 | |
| EA016034B1 (ru) | Комбинация соединений-ингибиторов меланогенеза и их применение в косметике и дерматологии | |
| KR20090098706A (ko) | 브라소카틀레야 마르셀라 코스 난초 추출물 및 피부 탈색제로서의 그의 용도 | |
| KR101985356B1 (ko) | 발효콩 추출물을 함유하는 피부 외용제 조성물 | |
| CN101095650B (zh) | 香豆素、丁基化的羟基茴香醚和乙氧喹治疗灰发症的用途 | |
| KR100886743B1 (ko) | 지페노사이드를 포함하는 피부 미백제 또는 발모제 | |
| CN115916146A (zh) | 白发抑制用组合物及其用途 | |
| KR20070021585A (ko) | 돌나물 추출물을 주요 활성성분으로 함유하는 피부외용제조성물 | |
| KR101971243B1 (ko) | 4'-o-메틸알피눔 이소플라본을 유효성분으로 포함하는 피부 미백용 조성물 | |
| SE1830383A1 (en) | Composition and formulation comprising a Persicaria Capitata plant extract | |
| KR102325393B1 (ko) | 소계 추출물의 생물전환물을 유효성분으로 함유하는 피부 미백용 화장료 조성물 | |
| JP5259127B2 (ja) | ツツジ科エリカ属植物由来成分を少なくとも含む外皮系組織用組成物 | |
| KR20170038321A (ko) | 텍토리게닌을 함유하는 두피 상태 개선 및/또는 육모 촉진용 조성물 | |
| KR102138462B1 (ko) | 네오마이신을 포함하는 피부 미백용 화장료 조성물 | |
| KR20130089559A (ko) | 항노화 조성물 | |
| CN114929239B (zh) | 用于防止脱发和促进生发的组合物 | |
| KR102186533B1 (ko) | 불가리안 로즈오일 및 바위돌꽃뿌리 추출물을 포함하는 피부 미백용 화장료 조성물 | |
| KR100820575B1 (ko) | 플라보노이드계 화합물을 포함하는 피부 미백용 조성물 | |
| KR100511114B1 (ko) | 항진균제를 함유한 피부 미백용 외용제 조성물 및 이를포함하는 미백용 외용제 | |
| JPH1029928A (ja) | 皮膚外用剤 | |
| KR20040060157A (ko) | 트라넥사믹산을 포함하는 피부 미백용 화장료 조성물 | |
| KR20240077016A (ko) | γ-망고스틴을 유효성분으로 포함하는 오토파지 활성에 따른 피부 노화 예방용 조성물 | |
| KR20240147912A (ko) | 쌀과 시금치의 혼합 추출물을 포함하는 항산화 및 미백 효과를 가지는 화장료 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |